Literature DB >> 2204938

Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines.

S L Kunkel1, R M Strieter, S W Chensue, M Basha, T Standiford, J Ham, D G Remick.   

Abstract

There is little doubt that the high degree of communication observed during an immune response occurs via sophisticated cell-to-cell mediator circuits. The coordinate expression of specific signals are needed to orchestrate inflammation as the lesion is initiated, maintained, and finally resolved. Each of these phases can be viewed as a unique window of inflammation that is driven by a specific set of mediators. In this manuscript, we have developed the concept that cytokine-cytokine interactions play a prominent role in the elicitation of inflammatory cells. Our data demonstrate that the expression of chemotactic cytokines are both cell and stimulus specific. Interleukin-8, neutrophil chemotactic factor, can be synthesized by a variety of immune and non-immune cells, but the production is dependent upon an appropriate challenge. The production of monocyte chemotactic factor is much more cell restricted and appears to be generated in abundance by only non-immune cells (fibroblasts, endothelial cells, and epithelial cells). These data suggest that the recruitment of cells to a site of inflammation is dependent upon the expression of specific cytokines for both the induction and maintenance of the lesion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204938

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  12 in total

1.  Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.

Authors:  Bipradeb Singha; Himavanth Reddy Gatla; Subrata Manna; Tzu-Pei Chang; Shannon Sanacora; Vladimir Poltoratsky; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2013-12-11       Impact factor: 5.157

2.  Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.

Authors:  Shannon Sanacora; Joaquin Urdinez; Tzu-Pei Chang; Ivana Vancurova
Journal:  Biochem Biophys Res Commun       Date:  2015-03-16       Impact factor: 3.575

3.  Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells.

Authors:  A Ueno; K Murakami; K Yamanouchi; M Watanabe; T Kondo
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

4.  IL-8 as a circulating cytokine: induction by recombinant tumour necrosis factor-alpha.

Authors:  N Sheron; R Williams
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

5.  Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.

Authors:  Subrata Manna; Bipradeb Singha; Sai Aung Phyo; Himavanth Reddy Gatla; Tzu-Pei Chang; Shannon Sanacora; Sitharam Ramaswami; Ivana Vancurova
Journal:  J Immunol       Date:  2013-07-26       Impact factor: 5.422

6.  Histopathological effects of intracerebral injections of human recombinant tumor necrosis factor-alpha in the rat.

Authors:  J L Wright; R E Merchant
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 7.  Computational modelling of the inflammatory response in trauma, sepsis and wound healing: implications for modelling resilience.

Authors:  Yoram Vodovotz
Journal:  Interface Focus       Date:  2014-10-06       Impact factor: 3.906

8.  Proinflammatory cytokines in allergic rhinitis.

Authors:  C Bachert; U Hauser; B Prem; C Rudack; U Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 9.  Transcriptional regulation of chemokine expression in ovarian cancer.

Authors:  Bipradeb Singha; Himavanth R Gatla; Ivana Vancurova
Journal:  Biomolecules       Date:  2015-03-17

10.  Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation.

Authors:  L H Faccioli; A I Medeiros; A Malheiro; R C Pietro; A Januário; B B Vargaftig
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.